Cue Biopharma Enters Material Definitive Agreement

Ticker: CUE · Form: 8-K · Filed: Jul 1, 2025 · CIK: 1645460

Sentiment: neutral

Topics: material-definitive-agreement, corporate-action

TL;DR

Cue Biopharma just signed a big deal, filing an 8-K on 6/30/25.

AI Summary

On June 30, 2025, Cue Biopharma, Inc. entered into a material definitive agreement. The company, formerly known as Imagen Biopharma, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.

Why It Matters

This filing indicates a significant new contract or partnership for Cue Biopharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering a material definitive agreement is a significant event that could carry substantial risks and rewards, warranting a medium risk assessment.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Cue Biopharma, Inc. on June 30, 2025?

The filing does not specify the details of the material definitive agreement, only that one was entered into on June 30, 2025.

What was Cue Biopharma, Inc.'s former company name?

Cue Biopharma, Inc.'s former company name was Imagen Biopharma, Inc.

Where are Cue Biopharma, Inc.'s principal executive offices located?

Cue Biopharma, Inc.'s principal executive offices are located at 40 Guest Street, Boston, Massachusetts 02135.

What is the SEC file number for this Form 8-K filing?

The SEC file number for this Form 8-K filing is 001-38327.

What is the IRS Employer Identification Number for Cue Biopharma, Inc.?

The IRS Employer Identification Number for Cue Biopharma, Inc. is 47-3324577.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Cue Biopharma, Inc. (CUE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing